Intellia rises after enrolling patients in late-stage trial of genetic disorder drug

** Shares of gene-editing firm Intellia Therapeutics NTLA.O rise 5.3% to $13.07 premarket

** Company says it has completed enrolling patients in a late-stage study of its experimental therapy, lonvoguran ziclumeran (lonvo-z), for the treatment of hereditary angioedema

** Hereditary Angioedema is characterized by severe, recurring, and unpredictable swelling attacks in parts of the body including the skin, gastrointestinal tract, and airways

** Company expects late-stage study data in H1 2026

** Intellia says it is on track to submit a biologics license application in H2 2026 to support the company's plans for a potential U.S. launch in H1 2027

** As of last close, stock up 6.4% YTD